Peng Z, Hung S, Fung K
Cancer Rep (Hoboken). 2025; 8(3):e70170.
PMID: 40034064
PMC: 11876858.
DOI: 10.1002/cnr2.70170.
Xiong X, Liu Y, Du Y, Lai X, Si C, Miao H
Discov Oncol. 2025; 16(1):245.
PMID: 40014170
PMC: 11868014.
DOI: 10.1007/s12672-025-02010-7.
Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J
Front Immunol. 2025; 16:1539396.
PMID: 39991153
PMC: 11842356.
DOI: 10.3389/fimmu.2025.1539396.
Wang P, Lu H, Zhang C, Wang R, Chen X, Qiao L
Sci Rep. 2025; 15(1):5484.
PMID: 39953179
PMC: 11829052.
DOI: 10.1038/s41598-025-89766-8.
Benjamin A, Nayak S
Discov Nano. 2025; 20(1):18.
PMID: 39883285
PMC: 11782756.
DOI: 10.1186/s11671-024-04163-w.
Research progress on N6-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential clinical applications.
Yang Y, Ni W, Yang Y, Liao J, Yang Y, Li J
Med Oncol. 2025; 42(3):55.
PMID: 39853585
DOI: 10.1007/s12032-024-02597-x.
Global, regional, and national burden of malignant neoplasm of bone and articular cartilage in adults aged 65 years and older, 1990-2021: a systematic analysis based on the global burden of disease study 2021.
Zhang X, Dai X, Chen Y, Wang S, Yang H, Qu B
Aging Clin Exp Res. 2025; 37(1):21.
PMID: 39776003
PMC: 11711276.
DOI: 10.1007/s40520-024-02926-0.
Delivery of IL-12 by neoantigen-reactive T cells promotes antitumor immunity in murine osteosarcoma mode.
Tian C, Sun X, Zhu H, Zhou M, Chen Q, Min D
Immunother Adv. 2025; 5(1):ltae010.
PMID: 39742319
PMC: 11684073.
DOI: 10.1093/immadv/ltae010.
New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing.
Zheng S, Luo M, Huang H, Huang X, Peng Z, Zheng S
Cell Commun Signal. 2024; 22(1):592.
PMID: 39696352
PMC: 11657588.
DOI: 10.1186/s12964-024-01989-w.
Trends and future directions of autophagy in osteosarcoma: A bibliometric analysis.
Shang J, Zhao F, Xie L, Wang Y, Li B, Jin C
Open Med (Wars). 2024; 19(1):20241080.
PMID: 39655055
PMC: 11627063.
DOI: 10.1515/med-2024-1080.
Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.
Li B, Zhao Q, Yang H, Wang X, Zhang Z, Gong Y
AAPS PharmSciTech. 2024; 25(8):272.
PMID: 39592553
DOI: 10.1208/s12249-024-02992-7.
Curcumin and Methotrexate: A Promising Combination for Osteosarcoma Treatment via Hedgehog Pathway Inhibition.
Giliberti G, Marrapodi M, Di Feo G, Pota E, Di Martino M, Di Pinto D
Int J Mol Sci. 2024; 25(20).
PMID: 39457084
PMC: 11509055.
DOI: 10.3390/ijms252011300.
AOC3 accelerates lung metastasis of osteosarcoma by recruiting tumor-associated neutrophils, neutrophil extracellular trap formation and tumor vascularization.
Qi L, Gao T, Bai C, Guo Z, Zhou L, Yang X
Heliyon. 2024; 10(17):e37070.
PMID: 39296147
PMC: 11408840.
DOI: 10.1016/j.heliyon.2024.e37070.
Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.
Chow T, Humble W, Lucarelli E, Onofrillo C, Choong P, Di Bella C
iScience. 2024; 27(9):110251.
PMID: 39286504
PMC: 11403063.
DOI: 10.1016/j.isci.2024.110251.
Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3β-ULK1 axis.
Feng Z, Ou Y, Deng X, Deng M, Yan X, Chen L
Cell Biosci. 2024; 14(1):111.
PMID: 39218913
PMC: 11367994.
DOI: 10.1186/s13578-024-01291-9.
Lipidomics by Nuclear Magnetic Resonance Spectroscopy and Liquid Chromatography-High-Resolution Mass Spectrometry in Osteosarcoma: A Pilot Study.
Pontes J, Jadranin M, Assalin M, Quintero Escobar M, Stanisic D, Carneiro Costa T
Metabolites. 2024; 14(8).
PMID: 39195512
PMC: 11356186.
DOI: 10.3390/metabo14080416.
LncRNA-encoded peptides in cancer.
Zhang Y
J Hematol Oncol. 2024; 17(1):66.
PMID: 39135098
PMC: 11320871.
DOI: 10.1186/s13045-024-01591-0.
Apoptotic Induction by Biosynthesized Gold Nanoparticles Using Strain AB_11_10 against Osteosarcoma Cancer.
Hamida R, AlMotwaa S, Al-Otaibi W, Alqhtani H, Ali M, Bin-Meferij M
Biomedicines. 2024; 12(7).
PMID: 39062143
PMC: 11274524.
DOI: 10.3390/biomedicines12071570.
LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review.
Hu S, Han X, Liu G, Wang S
Front Endocrinol (Lausanne). 2024; 15:1415722.
PMID: 39015175
PMC: 11249743.
DOI: 10.3389/fendo.2024.1415722.
Use of Period Analysis to Timely Assess Five-Year Relative Survival for the Patients With Bone Cancer.
Xie X, Zhao X, Li R, Cheng Y, Bing X, Yang J
World J Oncol. 2024; 15(4):675-681.
PMID: 38993259
PMC: 11236380.
DOI: 10.14740/wjon1875.